Prospective, randomized dose-ranging open phase II pilot study of quinupristin dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia

被引：30

作者：

Raad, I

Bompart, F

Hachem, R

机构：

[1] Univ Texas, MD Anderson Cancer Ctr, Dept Med Specialties, Sect Infect Control, Houston, TX 77030 USA

[2] Rhone Poulenc Rorer Cent Res, Collegeville, PA USA

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 1999年 / 18卷 / 03期

关键词：

D O I：

10.1007/s100960050258

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Two different doses of quinupristin/dalfopristin were compared with intravenous vancomycin with regard to the efficacy and safety in the treatment of catheter-related staphylococcal bacteremia. A total of 39 patients were enrolled from 13 centers. For all treated patients with a baseline pathogen, outcome was comparable for all antibiotic study regimens. Discontinuation of the antibiotic for an adverse clinical event occurred in 12% of patients receiving quinupristin/dalfopristin and in 15% of those receiving vancomycin. Quinupristin/dalfopristin may have the potential to serve as an alternative agent in the treatment of catheter-related staphylococcal bacteremia. However, larger prospective randomized trials are required.

引用

收藏

页码：199 / 202

页数：4

相关论文

共 12 条

[1] Gram-positive resistance: challenge for the development of new antibiotics [J].

Baquero, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :1-6

[2] In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin [J].

Bouanchaud, DH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :15-21

[3] VANCOMYCIN PENETRATION INTO BIOFILM COVERING INFECTED PROSTHESES AND EFFECT ON BACTERIA [J].

DAROUICHE, RO ;

DHIR, A ;

MILLER, AJ ;

LANDON, GC ;

RAAD, II ;

MUSHER, DM .

JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) :720-723

[4] VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM BACTEREMIA - RISK-FACTORS FOR INFECTION [J].

EDMOND, MB ;

OBER, JF ;

WEINBAUM, DL ;

PFALLER, MA ;

HWANG, T ;

SANFORD, MD ;

WENZEL, RP .

CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1126-1133

[5] STAPHYLOCOCCUS-EPIDERMIDIS EXTRACTED SLIME INHIBITS THE ANTIMICROBIAL ACTION OF GLYCOPEPTIDE ANTIBIOTICS [J].

FARBER, BF ;

KAPLAN, MH ;

CLOGSTON, AG .

JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (01) :37-40

[6] In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections [J].

Garcia, R ;

Raad, I .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (12) :933-936

[7] Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: A comparison with ciprofloxacin [J].

HamiltonMiller, JMT ;

Shah, S .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :103-108

[8] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].

Hiramatsu, K ;

Hanaki, H ;

Ino, T ;

Yabuta, K ;

Oguri, T ;

Tenover, FC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136

[9] In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus [J].

Kang, SL ;

Rybak, MJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :33-39

[10] Bloodstream infections with vancomycin-resistant enterococci [J].

Montecalvo, MA ;

Shay, DK ;

Patel, P ;

Tacsa, L ;

Maloney, SA ;

Jarvis, WR ;

Wormser, GP .

ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (13) :1458-1462